RecruitingNCT06373913

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom


Sponsor

Kolding Sygehus

Enrollment

75 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Nephrotic syndrome (NS) is characterized by gross proteinuria (\>3.5 g/day), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality. The study aim is to investigate the role of the protein convertase subtilisin/kexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses: 1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls 2. The level of PCSK9 in plasma correlates to the degree of proteinuria. 3. PCSK9 i increased in the kidney tissue of patients with NS The study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • years old
  • Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.

Exclusion Criteria4

  • Refusal to give informed consent
  • Treatment with PCSK9 inhibitors
  • Any acute or chronic condition that would limit the ability of the patient to participate in the study
  • Control group: proteinuria

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Kolding Sygehus, Lillebælt Hospital

Kolding, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06373913


Related Trials